Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Direct-acting antivirals (DAA) are highly effective at treating Hepatitis C virus (HCV) infection, with a cure rate >95%. However, the effect of DAAs on kidney function remains debated. METHODS: We analyzed electronic health record data for DAA-naive patients with chronic HCV infection engaged in HCV care at Boston Medical Center between 2014 and 2018. We compared the following hypothetical interventions using causal inference methods: 1) initiation of DAA and 2) no DAA initiation. For patients with normal kidney function at baseline (eGFR>90 ml/min/1.73m2), we estimated and compared the risk for reaching Stage 3 chronic kidney disease (CKD) (eGFR≤60 ml/min/1.73m2) under each intervention. For patients with baseline CKD Stages 2-4 (15

publication date

  • May 13, 2022

Research

keywords

  • Hepatitis C
  • Hepatitis C, Chronic
  • Renal Insufficiency, Chronic

Identity

PubMed Central ID

  • PMC9106151

Scopus Document Identifier

  • 85130015938

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0268478

PubMed ID

  • 35560032

Additional Document Info

volume

  • 17

issue

  • 5